JP2021119186A5 - - Google Patents

Download PDF

Info

Publication number
JP2021119186A5
JP2021119186A5 JP2021078504A JP2021078504A JP2021119186A5 JP 2021119186 A5 JP2021119186 A5 JP 2021119186A5 JP 2021078504 A JP2021078504 A JP 2021078504A JP 2021078504 A JP2021078504 A JP 2021078504A JP 2021119186 A5 JP2021119186 A5 JP 2021119186A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pridopidin
disease
huntington
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021078504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021119186A (ja
Filing date
Publication date
Priority claimed from JP2019531547A external-priority patent/JP6912574B2/ja
Application filed filed Critical
Publication of JP2021119186A publication Critical patent/JP2021119186A/ja
Publication of JP2021119186A5 publication Critical patent/JP2021119186A5/ja
Pending legal-status Critical Current

Links

JP2021078504A 2016-08-24 2021-05-06 機能低下を治療するためのプリドピジンの使用 Pending JP2021119186A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US62/379,175 2016-08-24
US201662395263P 2016-09-15 2016-09-15
US62/395,263 2016-09-15
US201662411511P 2016-10-21 2016-10-21
US62/411,511 2016-10-21
US201662416685P 2016-11-02 2016-11-02
US62/416,685 2016-11-02
JP2019531547A JP6912574B2 (ja) 2016-08-24 2017-08-24 機能低下を治療するためのプリドピジンの使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019531547A Division JP6912574B2 (ja) 2016-08-24 2017-08-24 機能低下を治療するためのプリドピジンの使用

Publications (2)

Publication Number Publication Date
JP2021119186A JP2021119186A (ja) 2021-08-12
JP2021119186A5 true JP2021119186A5 (cg-RX-API-DMAC7.html) 2021-10-28

Family

ID=61241181

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531547A Active JP6912574B2 (ja) 2016-08-24 2017-08-24 機能低下を治療するためのプリドピジンの使用
JP2021078504A Pending JP2021119186A (ja) 2016-08-24 2021-05-06 機能低下を治療するためのプリドピジンの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019531547A Active JP6912574B2 (ja) 2016-08-24 2017-08-24 機能低下を治療するためのプリドピジンの使用

Country Status (17)

Country Link
US (1) US11207310B2 (cg-RX-API-DMAC7.html)
EP (2) EP4516356A3 (cg-RX-API-DMAC7.html)
JP (2) JP6912574B2 (cg-RX-API-DMAC7.html)
CN (2) CN109923102B (cg-RX-API-DMAC7.html)
AU (2) AU2017315783C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019003732A2 (cg-RX-API-DMAC7.html)
CA (2) CA3151507C (cg-RX-API-DMAC7.html)
CL (2) CL2019000485A1 (cg-RX-API-DMAC7.html)
DK (1) DK3504187T3 (cg-RX-API-DMAC7.html)
ES (1) ES3025836T3 (cg-RX-API-DMAC7.html)
FI (1) FI3504187T3 (cg-RX-API-DMAC7.html)
HU (1) HUE071008T2 (cg-RX-API-DMAC7.html)
IL (1) IL311081A (cg-RX-API-DMAC7.html)
MX (2) MX390627B (cg-RX-API-DMAC7.html)
PL (1) PL3504187T3 (cg-RX-API-DMAC7.html)
PT (1) PT3504187T (cg-RX-API-DMAC7.html)
WO (1) WO2018039477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) * 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US10138241B2 (en) 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3917380B1 (en) * 2019-01-31 2025-03-19 F. Hoffmann-La Roche AG Assessing progression of huntington's disease
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
SMT202600016T1 (it) * 2019-06-12 2026-03-09 Prilenia Neurotherapeutics Ltd Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的s1rアゴニストを使用するウイルス感染、疾患、又は障害の治療
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
CA3214354A1 (en) * 2021-04-14 2022-10-20 Michael Hayden Treatment of prodromal huntington disease
WO2025164698A1 (ja) * 2024-01-31 2025-08-07 株式会社ケイファーマ ハンチントン病治療剤及び治療用組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
PE20071092A1 (es) 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070286902A1 (en) 2006-06-07 2007-12-13 Abrika Pharmaceuticals Dosage forms comprising a short acting sedative-hypnotic or salt thereof
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
WO2010008486A2 (en) * 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
BR112012006651B1 (pt) 2009-09-24 2021-11-03 Capsugel Belgium Nv Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20150209346A1 (en) 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2913781C (en) * 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤

Similar Documents

Publication Publication Date Title
JP2026048894A (ja) 5-メトキシ-n,n-ジメチルトリプタミンの安息香酸塩を含む組成物
JP2020143072A5 (cg-RX-API-DMAC7.html)
US5552429A (en) Potentiation of drug response
CA3182412A1 (en) Advantageous benzothiophene compositions for mental disorders or enhancement
JP2025004090A (ja) 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン
CN108883110B (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
WO2022061242A1 (en) Advantageous tryptamine compositions for mental disorders or enhancement
US12042481B2 (en) Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
JP2023126540A (ja) エンドキシフェンを製造および使用する方法
JP2022516662A (ja) S1p1受容体に関連する状態を治療する方法
JP2022535929A (ja) ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
AU2016222796A1 (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease
TW202400135A (zh) 包含阿替卡普蘭之組成物
EP0759299B1 (en) Potentiation of serotonin response
JP2025111439A (ja) トラピジルを使用した認知障害の治療
CN1891229A (zh) 预防或治疗代谢综合征的药物制剂
BR112013030093B1 (pt) comprimido revestido seco de desintegração oral contendo tegafur, gimeracilo e oteracilo potássico
WO2017000270A1 (zh) 枸橼酸舍曲林的2种晶型及其制备方法
CN101062039B (zh) 治疗神经系统疾病的药物组合物
US20080226714A1 (en) Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution
RU2775772C2 (ru) Норадренергический и специфически серотонинергический анксиолитик и антидепрессант, способ его получения и применения
KR20260065892A (ko) 주요 우울 장애의 치료에 사용하기 위한 아티카프란트를 포함하는 조성물
CN105061217A (zh) 枸橼酸舍曲林的2种晶型及其制备方法
TW202216674A (zh) 用於心理疾病或心理強化的有益苯并呋喃組合物
EA048593B1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов